2013 GU Cancers Symposium

ASCO GU: Finasteride Reduces Risk of Prostate Cancer Diagnosis

ASCO GU: Finasteride Reduces Risk of Prostate Cancer Diagnosis

Use of finasteride reduces the risk of a prostate cancer diagnosis, but does not significantly affect mortality rates after following men for 18 years, according to a study presented at the 2013 Genitourinary Cancers Symposium.

ASCO GU: Anticoagulant Use Predicts Metastatic Prostate CA Survival

ASCO GU: Anticoagulant Use Predicts Metastatic Prostate CA Survival

Anticoagulant use is associated with improved overall survival in men receiving docetaxel chemotherapy for treatment of mCRPC, according to research presented at the 2013 Genitourinary Cancers Symposium.

Urine-Based Biomarker Assay Can Detect Bladder Cancer Noninvasively

By

A urine-based assay "can markedly improve the accuracy" of detecting bladder cancer noninvasively, according to a case-controlled validation study reported during the 2013 Genitourinary Cancers Symposium.

No OS Difference Between Tivozanib and Sorafenib for Advanced Renal Cell Carcinoma

By

No significant difference in overall survival was found between tivozanib and sorafenib in patients with advanced renal cell carcinoma, according to research presented at the 2013 Genitourinary Cancers Symposium.

Sipuleucel-T Plus Abiraterone Acetate and Prednisone Comparable to Sipuleucel-T Alone in Men with mCRPC

By

Concurrent administration of sipuleucel-T and abiraterone acetate plus prednisone is comparable to sipuleucel-T alone in men with metastatic castration-resistant prostate cancer, according to research from the 2013 Genitourinary Cancers Symposium.

Serum Androgen Levels May Predict Survival in Castration-Resistant Prostate Cancer

By

Serum androgens appear to be prognostic of overall survival among men with castration-resistant prostate cancer, according to research presented at the 2013 Genitourinary Cancers Symposium.

Ra-223 'Significantly Improves' Survival in Bone-Metastatic Castration-Resistant Prostate Cancer

By

Radium-223 dichloride is associated with significant improvements in overall survival among patients with castration-resistant prostate cancer and bone metastases, according to research presented at the 2013 Genitourinary Cancers Symposium.

Corticosteroids During Enzalutamide Therapy Negatively Impact Survival Rates in Metastatic Castration-Resistant Prostate Cancer

By

Use of corticosteroids during treatment with enzalutamide reduces survival and increases adverse events in men with mCRPC who previously underwent docetaxel therapy, according to research presented at the 2013 Genitourinary Cancers Symposium.

Novel Antiandrogen Receptor, ARN-509, Shows Activity in Men with High-Risk Nonmetastatic CRPC

By

ARN-509 is safe and well tolerated in men with high-risk nonmetastatic castration-resistant prostate cancer, according to research presented at the 2013 Genitourinary Cancers Symposium.

Abiraterone Acetate Prolongs Survival in Metastatic Castration-Resistant Prostate Cancer

By

Abiraterone acetate prolongs survival among patients with metastatic castration-resistant prostate cancer who have not undergone prior chemotherapy, according to research presented at the 2013 Genitourinary Cancers Symposium.

Enzalutamide Monotherapy Induces PSA Response in Men with Hormone-Naïve Prostate Cancer

By

Monotherapy with the oral androgen receptor inhibitor, enzalutamide, was associated with significant prostate-specific antigen response in men with hormone-naïve prostate cancer, found research presented at the 2013 Genitourinary Cancers Symposium.

Elderly and African-American Men Face Increased Risk of Aggressive PSA-Detected Prostate Cancer

By

Prostate-specific antigen testing detects a significant number of high- to intermediate-risk T1cN0M0 stage prostate cancers among African American men as well as elderly men of any race or ethnicity, according to research presented at the 2013 Genitourinary Cancers Symposium.

Androgen Blockade Therapy for High-Risk Prostate Cancer Can Be Safely Reduced to 18 Months

By

Reducing androgen blockade therapy from 36 months to 18 months for men with high-risk prostate cancer does not harm patients' survival times, according to a prospective randomized phase 3 clinical trial reported at the 4th annual 2013 Genitourinary Cancers Symposium.

Surveillance Safe Option for Elderly Patients with Small Renal Masses

By

Surveillance is an option for older patients with small renal masses for whom surgery is unacceptable, according to research presented at the 2013 Genitourinary Cancers Symposium.

ChemotherapyAdvisor.com Editorial Board Recommends High-Impact Abstracts from the 2013 Genitourinary Cancers Symposium

ChemotherapyAdvisor.com Editorial Board Recommends High-Impact Abstracts from the 2013 Genitourinary Cancers Symposium

By

Dr. Neal Shore, MD, FACS, of Atlantic Urology Clinics shares his list of recommended abstracts that will be presented at the 2013 Genitourinary Cancers Symposium.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs